A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Clinical trial NCT05789082 · RECRUITING
Trial details
- NCT number
- NCT05789082
- Sponsor
- Hoffmann-La Roche
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-20
- Primary completion
- 2032-01-29
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.